托伐普坦  99.0552%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

库存{{model.attbuying.number}}
熔点:223 - 229℃
包装规格:250mg 1g 5g in glass bottle
产品简介:一种精氨酸加压素受体2拮抗剂,能抑制AVP-诱导的血小板聚集,IC50为1.28μM。
溶解性:溶于DMSO(≥100mg/mL)
储备液保存:-80°C, 2 years; -20°C, 1 year。
体内实验:1、请依序添加每种溶剂: 10% DMSO→40% PEG300→5% Tween-80→ 45% Saline Solubility: ≥ 2.17 mg/mL (4.83 mM); 澄清溶液 此方案可获得 ≥ 2.17 mg/mL(饱和度未知)的澄清溶液。 以 1 mL 工作液为例,取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL。 2、请依序添加每种溶剂: 10% DMSO→90% Corn Oil Solubility: ≥ 2.17 mg/mL (4.83 mM); 澄清溶液 此方案可获得 ≥ 2.17 mg/mL(饱和度未知)的澄清溶液,此方案实验周期在半个月以上的动物实验酌情使用。 以 1 mL 工作液为例,取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中,混合均匀。 注:工作液建议您现用现配,当天使用。 <1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
靶点:V2 Receptor
体外研究:Tolvaptan (0-100 μM;24-168 小时) 可降低 HepG2 细胞的生长。 Tolvaptan (20-100 μM;24-48 小时) 诱导 HepG2 细胞死亡。 Tolvaptan (0-100 μM;24-48 小时) 影响 HepG2 细胞周期. Tolvaptan (0-100 μM;24-48 小时) 引起 DNA 损伤并诱导 HepG2 细胞凋亡。 Tolvaptan (0-100 μM ; 24-48 小 时 ) 在 HepG2 细 胞 中 降 低 细 胞 周 期 蛋白和CDKs ,增加γ-H2AX, PARP 切割和 LC3B-II。 Tolvaptan (0-100 μM;4-24 小时) 诱导 HepG2 细胞中 JNK、ERK1/2 和 p38 的磷酸化。 Tolvaptan (0-100 μM;24-28 小时) 诱导 HepG2 细胞自噬。
体内研究:Tolvaptan (10mg /kg;每日 1 次,连用 22 天) 可改善环磷酰胺 (CP) 所致大鼠肾毒性。
细胞实验:Cell Viability Assay Cell Line:HepG2 cells Concentration:0-100 μM Incubation Time:24, 48, 96 and 168 hours Result:Time- and dose-dependently inhibited HepG2 cells with IC50s of >100, 52.2, 33.0 and 27.1 μM at 24, 48, 96 and 168 hours, respectively. Cell Viability Assay Cell Line:HepG2 cells Concentration:20, 40, 60, 80, and 100 μM Incubation Time:24 and 48 hours Result:Time- and dose-dependently inhibited HepG2 cell growth and caused cell death, with LDH released at a concentration over 40 μM. Caused oxidative DNA damage and increased ROS production with a concentration of 60-100 μM. Cell Cycle Analysis Cell Line:HepG2 cells Concentration:0-100 μM Incubation Time:24 and 48 hours Result:Caused cell cycle arrest at the G2 phase, dose-dependently increased the percentage of G0/G1 phase cells with a concentration of 20-60 μM and increased the percentage of G2/M phase cells with a concentration of 60-100 μM. Western Blot Analysis Cell Line:HepG2 cells Concentration: 0-100 μM Incubation Time:24 and 48 hours Result:Dose-dependently decreased cyclin D1, cyclin D3, cyclin B1, CDK1, CDK2, CDK4, and CDK6, and increased γ-H2AX which is a maker of DNA double strand breaks in HepG2 cells. Increased the full length PARP into cleavage situation and induced PARP cleavage. Apoptosis Analysis Cell Line:HepG2 cells Concentration:0-100 μM Incubation Time:24 and 48 hours Result:Induced cell apoptosis with increasing caspase 3/7 activity at a dose over 40 μM. Western Blot Analysis Cell Line:HepG2 cells Concentration:0-100 μM Incubation Time:4 and 24 hours Result:Induced the activation of ERK1/2 and p38 after 4 or 24 h of exposure at a concentration over 60 μM in HepG2 cells. Cell Autophagy Assay Cell Line:HepG2 cells Concentration:0-100 μM Incubation Time:24 and 48 hours Result:Induced cell autophagy with autophagosome formation and an increasing lysosomal turnover rate.
动物实验:Animal Model:Male albino rats with cyclophosphamide intraperitoneal injection Dosage:10 mg/kg Administration:Oral gavage; 10 mg/kg once per day; for 22 days Result:Improved the level of urine volume, serum Na+, serum osmolarity, urinary creatinine, free water clearance, serum creatinine, urea, serum K+, blood pressure, urine osmolarity, fractional excretion of sodium and signs of nephrotoxicity in mice. Decreased caspase-3, Bax and pro-inflammatory cytokines, and increased antiapoptotic Bcl-2 in renal tissue of mice.
保存条件:2-8℃
注意事项:1、为了您的安全和健康,请穿实验服并戴一次性手套操作。 2、以上信息仅做参考交流之用。